 Heidelberg, Germany, March 10, 2021 Affimed N.V. Nasdaq: AFMD, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that preclinical anti-tumor efficacy in vivo data from its innate cell engager ICE AFM24 have been accepted for e-poster presentation at the American Association for Cancer Research AACR Virtual Annual Meeting I, being held on April 10-15. 